LRRK2 and Parkinson disease: LRRK2’s central role in mitochondrial dysfunction associated with PD, coupled with the previous failures in developing mitochondrial therapeutics for PD, highlights the necessity to acknowledge heterogeneity in PD pathogenesis and develop treatments that target PD stratification based on different biological sources of PD etiology (Figure 3) [222–225].